PSS12 NEPAFENAC FOR THE REDUCTION IN RISK OF POST-OPERATIVE MACULAR OEDEMA ASSOCIATED WITH CATARACT SURGERY IN DIABETIC PATIENTS: A COST-EFFECTIVENESS ESTIMATION FOR SCOTLAND

OBJECTIVES:
Treatment strategies for the prevention of macular oedema (MO) in diabetic patients include the postoperative use of steroids with and without antibiotics. However, measured with optimal coherence tomography (OCT), between 14% and 22% of diabetic patients still experience postoperative MO, with 3.05% developing clinically significant MO (CSMO). Nepafenac has recently been granted approval in Scotland for the licensed indication of reduction in risk of postoperative MO associated with cataract surgery in diabetic patients. The primary objective was to therefore estimate the incremental cost-effectiveness ratio (ICER) of Nepafenac compared to the identified standard practice of Prednisolone Acetate Ophthalmic Suspension (PAOS). METHODS: An Excel-based cost-utility model was developed with a 90-day time horizon (base-case). An appropriate comparator was established via consultation with an expert advisory-board comprised of 3 ophthalmologists currently practising in Scotland. Effectiveness data were derived from the pivotal study, C-07-43, whereby the primary outcome demonstrated that a significantly smaller percentage of patients in the Nepafenac group developed MO relative to patients in the vehicle group (3.2% vs 16.7%; pϽ0.001). The difference at 90 days was converted to a RR of MO ϭ 0.19. Costs comprised drug acquisition and outpatient costs, the latter including physician visits and OCT, derived from ISD Scotland and the BNF 63. Importantly, costs were only associated with those patients with clinically diagnosed MO. In terms of utilities, an algorithm associating logMAR visual acuity (VA) with health-related utility estimated with TTO was used to populate the model. RESULTS: Nepafenac had an ICER of £6,552 per QALY compared to PAOS in the base-case scenario. CONCLUSIONS: Nepafenac is highly cost-effective compared to Prednisolone Acetate, and with a concomitant low budget impact (estimated annual maximum of £110,500), should be considered as the primary treatment for reduction in risk of postoperative MO associated with cataract surgery in diabetic patients. 
PSS13 COST-EFFECTIVENESS OF SPECIALIZED TREATMENT BASED ON COGNITIVE BEHAVIOURAL THERAPY VERSUS USUAL CARE FOR TINNITUS
OBJECTIVES:
Up to 21% of adults will develop tinnitus, manifesting the perception of a noxious disabling internal sound. Many different treatments are offered, but evidence on their effectiveness and cost-effectiveness is scarce or absent. Recently, the effectiveness of a specialised treatment of tinnitus based on cognitive behavioural therapy was demonstrated (Cima et al., 2012) . The present study evaluates the cost-effectiveness of this treatment compared to care as usual, in an audiological centre. METHODS: An economic evaluation was carried out alongside a randomized controlled clinical trial. The economic evaluation was conducted from a societal perspective, using a one-year time horizon. The incremental cost effectiveness ratio (iCER) was calculated by dividing the difference in costs by the difference in Quality Adjusted Life Years (QALYs) based on the HUI Mark III. Non-parametric bootstrapping and sensitivity analyses were used to asses the uncertainty in costs and effects. Sensitivity analysis included a complete cases analysis and analysis on data were missing values on the HUI mark III were imputed based on a mixed regression model from the clinical effectiveness analysis. RESULTS: Compared to patients receiving usual care, patients who received specialised care gained on average 0.015 QALYs (BCI:-0.028-0.055) The incremental costs from a societal perspective are €286 (BCI:-€828-€1427). The incremental cost per QALY from a societal perspective amounted to €19,688. The probability that SC is cost-effective from a societal perspective is 57% for a willingness to pay for a QALY of €35,000. CONCLUSIONS: Specialised multidisciplinary tinnitus based on cognitive behavioural therapy is cost-effective as compared to usual care. Although uncertainty surrounding the incremental costs and effects is considerable, sensitivity analysis indicated that cost-effectiveness results were robust. OBJECTIVES: Etanercept, infliximab, ustekinumab, and adalimumab have been granted marketing authorization for the treatment of moderate-to-severe psoriasis in Germany. The objective of this study is to evaluate cost-effectiveness of biologic treatments from the German Social Health Insurance (SHI) perspective. METHODS: A simple decision model was constructed to assess the cost-effectiveness of biologics compared to supportive care for the treatment of moderate-to-severe psoriasis over a one-year time horizon. Clinical efficacy was based on the relative probabilities of achieving PASI75, and PASI 90 response obtained via a network metaanalysis. Weight-based dosing was assumed for infliximab and ustekinumab. Costs were assessed in terms of 2012 euros, and included drug acquisition, administration, laboratory tests, clinic visits, and hospitalization costs. Cost-effectiveness from payer perspective was assessed as the cost-per-PASI75 response and cost-per-PASI90 response compared with supportive care (no systemic therapy) over a one-year time horizon. One-way sensitivity analyses, where key parameters were changed to alternative plausible values, explored uncertainty in the results. RESULTS: In the base case, adalimumab was found to be the most cost-effective compared to supportive care (€25,378 per PASI75 responder and €46,870 per PASI90 responder), followed by infliximab (€30,719 per PASI75 responder and €47,300 per PASI90 responder), ustekinumab (€31,953 per PASI75 responder, and €57,852 per PASI90 responder), etanercept 50mg BIW (€43,049 per PASI75 responder and €101,306 per PASI90 responder), and etanercept 25 mg BIW (€43,156 per PASI75 responder and €111,369 per PASI90 responder). The incremental cost per PASI 75 responder gained and the incremental cost per PASI 90 for infliximab compared to adalimumab were €51,812 and €48,112, and €87,942 and €106,911 respectively for ustekinumab. Adalimumab remained the most cost-effective over the vast majority of the one-way sensitivity analyses. CONCLUSIONS: This study found that adalimumab is the most cost-effective biologic treatment for moderate to severe psoriasis from the German SHI perspective. OBJECTIVES: Atopic dermatitis (AD) affects more than 15% of the population carrying a heavy burden in developed countries and leading to significant losses in patients' quality of life, especially in children. Although no cure has yet been found for AD, novel drugs such as tacrolimus have been released in recent years. Therefore this study aimed to perform a cost-effectiveness analysis comparing tacrolimus 0.1% ointment with ciclosporin 100mg for the treatment of moderate to severe AD from the Portuguese societal perspective. METHODS: An individual simulation event process was designed to mimic the natural course and treatment of the disease, including relapse and maintenance phases. Time to remission and time to relapse were simulated according to data from a 6-week randomised trial between A570 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) A 2 7 7 -A 5 7 5
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